CN1809573A - 三环吲哚衍生物和它们在治疗阿尔茨海默病中的用途 - Google Patents

三环吲哚衍生物和它们在治疗阿尔茨海默病中的用途 Download PDF

Info

Publication number
CN1809573A
CN1809573A CNA2004800175617A CN200480017561A CN1809573A CN 1809573 A CN1809573 A CN 1809573A CN A2004800175617 A CNA2004800175617 A CN A2004800175617A CN 200480017561 A CN200480017561 A CN 200480017561A CN 1809573 A CN1809573 A CN 1809573A
Authority
CN
China
Prior art keywords
alkyl
amino
methyl
ethyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800175617A
Other languages
English (en)
Chinese (zh)
Inventor
伊曼纽尔·H·德蒙特
萨利·雷德肖
达里尔·S·沃尔特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN1809573A publication Critical patent/CN1809573A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/06—Peri-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CNA2004800175617A 2003-04-23 2004-04-21 三环吲哚衍生物和它们在治疗阿尔茨海默病中的用途 Pending CN1809573A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0309221.0 2003-04-23
GBGB0309221.0A GB0309221D0 (en) 2003-04-23 2003-04-23 Novel compounds

Publications (1)

Publication Number Publication Date
CN1809573A true CN1809573A (zh) 2006-07-26

Family

ID=9957152

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800175617A Pending CN1809573A (zh) 2003-04-23 2004-04-21 三环吲哚衍生物和它们在治疗阿尔茨海默病中的用途

Country Status (16)

Country Link
US (1) US20060229302A1 (https=)
EP (1) EP1620438A1 (https=)
JP (1) JP2006524206A (https=)
KR (1) KR20050111797A (https=)
CN (1) CN1809573A (https=)
BR (1) BRPI0409622A (https=)
CA (1) CA2523291A1 (https=)
CO (1) CO5700829A2 (https=)
GB (1) GB0309221D0 (https=)
IS (1) IS8135A (https=)
MA (1) MA27674A1 (https=)
MX (1) MXPA05011365A (https=)
NO (1) NO20055442L (https=)
RU (1) RU2005136370A (https=)
WO (1) WO2004094430A1 (https=)
ZA (1) ZA200508041B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351738B2 (en) * 2002-11-27 2008-04-01 Elan Pharmaceuticals, Inc. Substituted ureas and carbamates
GB0328900D0 (en) * 2003-12-12 2004-01-14 Glaxo Group Ltd Novel compounds
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
GB0411404D0 (en) * 2004-05-21 2004-06-23 Glaxo Group Ltd Novel compounds
BRPI0515383A (pt) * 2004-09-21 2008-07-22 Pfizer Prod Inc n-etil hidroxietilamina útil no tratamento de condições do snc
GB0422765D0 (en) * 2004-10-13 2004-11-17 Glaxo Group Ltd Novel compounds
GB0422766D0 (en) * 2004-10-13 2004-11-17 Glaxo Group Ltd Novel compounds
GB0422755D0 (en) * 2004-10-13 2004-11-17 Glaxo Group Ltd Novel compounds
WO2006088705A1 (en) * 2005-02-14 2006-08-24 Wyeth Terphenyl guanidines as [beta symbol] -secretase inhibitors
GB0506562D0 (en) * 2005-03-31 2005-05-04 Glaxo Group Ltd Novel compounds
KR20080015079A (ko) 2005-04-08 2008-02-18 코멘티스, 인코포레이티드 베타 세크레타제 활성을 억제하는 화합물 및 이것의 사용방법
US20090170830A1 (en) * 2005-08-03 2009-07-02 Nantermet Philippe G Tricyclic Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease
US7838676B2 (en) * 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
WO2007061670A1 (en) * 2005-11-21 2007-05-31 Amgen Inc. Beta-secretase modulators and methods of use
US7745484B2 (en) 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
US7872009B2 (en) * 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
CA2687608C (en) 2007-05-25 2013-07-02 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
US8163909B2 (en) 2007-05-25 2012-04-24 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
FR2919285B1 (fr) 2007-07-27 2012-08-31 Sanofi Aventis Derives de 1-oxo-isoindoline-4-carboxamides et de 1-oxo- 1,2,3,4-tetrahydroisoquinoleine-5-carboxamides, leur preparation et leur application en therapeutique.
PT2185561E (pt) * 2007-07-27 2011-09-07 Sanofi Aventis Derivados de 1,2,3,4-tetra-hidropirrolo(1,2-a)pirazina-6- carboxamidas e de 2,3,4,5-tetra-hidropirrolo(1,2-a)-diazepina-7- carboxamidas, sua preparação e sua aplicação em terapia
FR2919289B1 (fr) * 2007-07-27 2009-09-04 Sanofi Aventis Sa Derives de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]- diazepine-7-carboxamides, leur preparation et leur application en therapeutique.
FR2919288B1 (fr) * 2007-07-27 2009-09-04 Sanofi Aventis Sa Derives de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6- carboxamides, leur preparation et leur application en therapeutique.
FR2919286A1 (fr) 2007-07-27 2009-01-30 Sanofi Aventis Sa Derives de derives de 1-oxo-1,2-dihydroisoquinoleine-5- carboxamides et de 4-oxo-3,4-dihydroquinazoline-8- carboxamides,leur preparation et leur application en therapeutique.
WO2013148130A1 (en) * 2012-03-29 2013-10-03 Oklahoma Medical Research Foundation Inhibition of memapsin 1 cleavage in the treatment of diabetes
MX2020003242A (es) * 2017-09-22 2020-09-18 Jubilant Epipad LLC Compuestos heterociclicos como inhibidores de pad.
WO2019075358A1 (en) * 2017-10-13 2019-04-18 Ghosh Arun K BACE1 INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
US12043631B2 (en) 2017-10-13 2024-07-23 Purdue Research Foundation BACE1 inhibitors for the treatment of Alzheimer's disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2280096A1 (en) * 1997-02-04 1998-08-06 The Regents Of The University Of California Nanomolar, non-peptide inhibitors of cathepsin d
US6207664B1 (en) * 1998-11-25 2001-03-27 Pfizer Inc. Squalene synthetase inhibitor agents
EP1299352B1 (en) * 2000-06-30 2005-12-28 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease

Also Published As

Publication number Publication date
CO5700829A2 (es) 2006-11-30
JP2006524206A (ja) 2006-10-26
MXPA05011365A (es) 2005-11-28
CA2523291A1 (en) 2004-11-04
GB0309221D0 (en) 2003-06-04
EP1620438A1 (en) 2006-02-01
MA27674A1 (fr) 2005-12-01
BRPI0409622A (pt) 2006-04-18
ZA200508041B (en) 2007-02-28
AU2004232475A1 (en) 2004-11-04
KR20050111797A (ko) 2005-11-28
IS8135A (is) 2005-11-21
NO20055442L (no) 2005-11-17
US20060229302A1 (en) 2006-10-12
RU2005136370A (ru) 2006-05-27
WO2004094430A1 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
CN1809573A (zh) 三环吲哚衍生物和它们在治疗阿尔茨海默病中的用途
CN1151787C (zh) 乳胱氨酸类似物
CN1093123C (zh) 芳烷基和芳基亚烷基杂环的内酰胺及酰亚胺
CN1280269C (zh) 脂肪族含氮五员环化合物
CN1745081A (zh) 二氢蝶啶酮、其制法及作为药物制剂的用途
CN1837207A (zh) 吡嗪并(氮杂)吲哚衍生物
CN101076532A (zh) 作为甘氨酸转运体I(GlyT－1)抑制剂用于治疗阿尔茨海默氏病的二环和三环取代的苯甲酮化合物
CN1620455A (zh) 作为5－羟色胺－6配体的氮杂吲哚基烷基胺衍生物
CN101035795A (zh) 噻唑基二氢吲唑
CN1093859C (zh) 新型吲哚－2,3－二酮－3－肟衍生物
CN1494422A (zh) Gabaa反相激动剂与烟碱受体不完全激动剂、雌激素、选择性雌激素调节剂、或维生素e联合用于认知障碍的用途
CN1914214A (zh) 三环吲哚羟乙基胺衍生物和它们在治疗阿尔茨海默病中的用途
CN1646528A (zh) 作为有效的α2－肾上腺素受体拮抗剂的多环化合物
CN1761673A (zh) 胍衍生物及其作为神经肽ff受体拮抗剂的用途
CN1117092C (zh) 氮杂双环化合物,其药物组合物及医药用途
CN1812992A (zh) Hiv整合酶抑制剂
CN1418216A (zh) 新的2,3,4,5－四氢－1H－[1,4]二氮杂䓬并[1,7－a]吡哚化合物
CN1103534A (zh) 具有抗精神病作用的化合物
CN1159315C (zh) 4,5-吡咯并羟吲哚
CN100349887C (zh) 取代的4－芳基－4h－吡咯并[2,3－h]色烯和类似物及其药物组合物和用途
CN1511034A (zh) 用于治疗与过度细胞因子活性相关的疾病的异噁唑酮化合物
CN1993367A (zh) 稠合的嘧啶衍生物和黄嘌呤氧化酶抑制剂
CN1835956A (zh) 酰化和非酰化的咪唑并[2,1－b]－1,3,4,－噻二唑－2－磺酰胺及其用途
CN1247589C (zh) 具有抗血管生成活性的吲哚的三环衍生物
CN1195757C (zh) 光学纯的喜树碱类似物及组合物和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
C20 Patent right or utility model deemed to be abandoned or is abandoned